Entera Bio (ENTX) Current Assets (2017 - 2026)

Entera Bio (ENTX) has reported Current Assets for 10 consecutive years, with $12.5 million the latest figure, recorded in Q1 2026.

• Quarterly Current Assets fell 41.12% year-over-year to $12.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (down 41.12% YoY) and the FY2025 annual result came in at $15.3 million, up 70.51% from the prior year.
• Current Assets declined to $12.5 million in Q1 2026 per ENTX's latest filing, from $15.3 million in the prior quarter.
• Over the last five years, Current Assets for ENTX reached as high as $21.6 million in Q1 2022 and fell as low as $7.3 million in Q3 2024.
• A 5-year average of $13.5 million and a median of $12.5 million in 2026 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets sank 49.27% — and 2025, when it jumped 131.7%.
• Year by year, Current Assets stood at $12.8 million in 2022, then dropped by 12.39% to $11.3 million in 2023, then fell by 20.3% to $9.0 million in 2024, then jumped by 70.51% to $15.3 million in 2025, then retreated by 18.34% to $12.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $12.5 million, $15.3 million, and $17.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.